186 related articles for article (PubMed ID: 10907030)
1. [Tissue plasminogen activator antigen (t-PA Ag) and tissue plasminogen activator inhibitor (PAI-1) in the course of hemodialysis in patients with chronic renal failure].
Piatkowska M; Kotschy M; Nartowicz E; Rajewski W
Pol Merkur Lekarski; 1997 Jan; 2(9):205-7. PubMed ID: 10907030
[TBL] [Abstract][Full Text] [Related]
2. Fibrinolytic activity during hemodialysis: a biocompatibility-related phenomenon.
Martin-Malo A; Velasco F; Rojas R; Castillo D; Rodriguez M; Torres A; Aljama P
Kidney Int Suppl; 1993 Jun; 41():S213-6. PubMed ID: 8320924
[TBL] [Abstract][Full Text] [Related]
3. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
4. Enhanced fibrinolytic activity during the course of hemodialysis.
Nakamura Y; Tomura S; Tachibana K; Chida Y; Marumo F
Clin Nephrol; 1992 Aug; 38(2):90-6. PubMed ID: 1387598
[TBL] [Abstract][Full Text] [Related]
5. [Hypofibrinolysis after venous occlusion in patients treated with long-term hemodialysis].
Opatrný K; Vít L; Opatrná S; Sulková S; Bodláková B
Cas Lek Cesk; 1994 May; 133(11):346-9. PubMed ID: 8004664
[TBL] [Abstract][Full Text] [Related]
6. Levels of fibrinolytic activators and inhibitors in plasma after severe trauma.
Sørensen JV
Blood Coagul Fibrinolysis; 1994 Feb; 5(1):43-9. PubMed ID: 7514044
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of fibrinolytic capacity by a combined assay system for tissue-type plasminogen activator antigen and function using monoclonal anti-tissue-type plasminogen activator antibodies.
Wojta J; Turcu L; Wagner OF; Korninger C; Binder BR
J Lab Clin Med; 1987 Jun; 109(6):665-71. PubMed ID: 3108431
[TBL] [Abstract][Full Text] [Related]
8. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
[TBL] [Abstract][Full Text] [Related]
9. Tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-I (PAI-I) levels in plasma and peritoneal effluent in patients on CAPD.
Selgas R; Cuesta MV; Riñon C; Romero JR; de Alvaro F; Bajo MA; Sanchez-Sicilia L
Adv Perit Dial; 1992; 8():160-5. PubMed ID: 1361777
[TBL] [Abstract][Full Text] [Related]
10. [Fluctuations of tissue-type plasminogen activator.plasminogen activator inhibitor-1 complex in patients with DIC].
Nagaizumi K; Kuroso K; Amano K; Sato T; Fukutake K; Fujimaki M
Rinsho Byori; 1994 Jul; 42(7):707-12. PubMed ID: 8065036
[TBL] [Abstract][Full Text] [Related]
11. [Tissue type plasminogen activator and its inhibition in blood of patients operated on for prostatic carcinoma].
Iwan-Zietek I; Zietek Z; Kotschy M; Rość D; Tyloch F
Pol Tyg Lek; 1996 Feb; 51(6-9):91-3. PubMed ID: 8756741
[TBL] [Abstract][Full Text] [Related]
12. Tissue-type plasminogen activator after venous occlusion in pregnancy and puerperium.
Stegnar M; Zore A; Novak-Antolic Z; Vovk N; Kruithof EK
Thromb Haemost; 1993 Sep; 70(3):486-90. PubMed ID: 8259554
[TBL] [Abstract][Full Text] [Related]
13. Tissue plasminogen activator as a hemodialysis catheter locking solution.
McGill RL; Spero JA; Sysak JC; Sandroni SE; Marcus RJ
Hemodial Int; 2008 Jul; 12(3):348-51. PubMed ID: 18638092
[TBL] [Abstract][Full Text] [Related]
14. The fibrinolytic system in chronic renal failure.
Lottermoser K; Petras S; Pöge U; Fimmers R; Hertfelder HJ; Schiermeyer B; Vetter H; Düsing R
Eur J Med Res; 2001 Sep; 6(9):372-6. PubMed ID: 11591527
[TBL] [Abstract][Full Text] [Related]
15. [Plasminogen activators (t-PA and u-PA) and other fibrinolysis parameters in patients with atherosclerosis obliterans and diabetic macroangiopathy].
Zalewska-Rydzkowska D; Rość D; Ponikowska I; Michalski A; Graczykowska-Koczorowska A; Rydzkowski M
Pol Merkur Lekarski; 2001 Nov; 11(65):414-7. PubMed ID: 11852811
[TBL] [Abstract][Full Text] [Related]
16. Tissue plasminogen activator release in chronic venous hypertension due to heart failure.
Keber I; Keber D; Stegnar M; Vene N
Thromb Haemost; 1992 Sep; 68(3):321-4. PubMed ID: 1440498
[TBL] [Abstract][Full Text] [Related]
17. Modulation of tissue plasminogen activator and plasminogen activator inhibitor-1 by transforming growth factor-beta in human retinal glial cells.
Schacke W; Beck KF; Pfeilschifter J; Koch F; Hattenbach LO
Invest Ophthalmol Vis Sci; 2002 Aug; 43(8):2799-805. PubMed ID: 12147618
[TBL] [Abstract][Full Text] [Related]
18. [Plasminogen tissue activator and plasminogen tissue inhibitor in type II diabetes].
Rość D; Drewniak W; Kotschy M; Graczykowska-Koczorowska A; Raukuć D
Pol Merkur Lekarski; 1997 Jan; 2(7):24-5. PubMed ID: 9296893
[TBL] [Abstract][Full Text] [Related]
19. Fibrinolysis system in patients with bronchial asthma.
Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
[TBL] [Abstract][Full Text] [Related]
20. Production of tissue-type plasminogen activator (t-PA) and type-1 plasminogen activator inhibitor (PAI-1) in mildly cirrhotic rat liver.
Seki T; Imai H; Uno S; Ariga T; Gelehrter TD
Thromb Haemost; 1996 May; 75(5):801-7. PubMed ID: 8725727
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
